Natasha K. Stout
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natasha K. Stout has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Melamed
Massachusetts General Hospital, Boston, MA
12 shared publications - Brandy M. Heckman-Stoddard
National Cancer Institute 10 Rockville, MD
12 shared publications - Chin Hur
Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA
12 shared publications - Chung Yin Kong
Division of General Internal Medicine Icahn School of Medicine at Mount Sinai New York New York USA
12 shared publications - Elena B. Elkin
Department of Health Policy and Management, Columbia University Mailman School of Public Health, New York, NY
12 shared publications - Evan R. Myers
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
12 shared publications
Latest Publications
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 486-496
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations
Federally mandated breast density notifications motivate consideration of supplemental breast magnetic resonance imaging (MRI). To evaluate supplemental breast MRI strategies. Simulation of women at average to 4 times higher-than-average relative risk (RR) for breast cancer incidence undergoing screening digital breast tomosynthesis (DBT) with or without supplemental MRI. Breast Cancer Surveillance Consortium and literature. Women aged 40 years or older. Lifetime. U.S. federal payer. Screening with DBT with or without breast density-targeted MRI by starting age (40, 45, or 50 years) and interval (annual or biennial). Breast cancer deaths averted, false-positive biopsy recommendations, harm-benefit ratios, and incremental cost-effectiveness ratios (ICERs). Across all starting ages and intervals, DBT averted 7.4 to 10.5 breast cancer deaths per 1000 average-risk women screened and 23.2 to 33.6 per 1000 women with 4 times higher-than-average risk. Across all RR levels, DBT with supplemental MRI for women with extremely dense breasts (DBT+MRId) averted 0.1 to 0.8 additional breast cancer deaths and resulted in 22 to 186 additional false-positive biopsy recommendations. False-positive biopsies per breast cancer death averted for biennial DBT+MRId for women with 2 times higher-than-average risk were similar to those associated with DBT in average-risk women. For all risk groups, biennial DBT+MRId starting at age 50 years was more effective but less cost-effective than DBT starting at age 45 years. The ICERs were sensitive to cancer risk, MRI costs, and false-positive biopsy rates. Subgroups considered risk and breast density only. Supplemental MRI for women aged 40 years or older with extremely dense breasts and higher-than-average risk (RR ≥2.0) had harm-benefit ratios similar to biennial DBT alone and could be cost-effective if MRI costs and false-positive biopsy rates are reduced. National Cancer Institute.
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 486-496
Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations
Federally mandated breast density notifications motivate consideration of supplemental breast magnetic resonance imaging (MRI). To evaluate supplemental breast MRI strategies. Simulation of women at average to 4 times higher-than-average relative risk (RR) for breast cancer incidence undergoing screening digital breast tomosynthesis (DBT) with or without supplemental MRI. Breast Cancer Surveillance Consortium and literature. Women aged 40 years or older. Lifetime. U.S. federal payer. Screening with DBT with or without breast density-targeted MRI by starting age (40, 45, or 50 years) and interval (annual or biennial). Breast cancer deaths averted, false-positive biopsy recommendations, harm-benefit ratios, and incremental cost-effectiveness ratios (ICERs). Across all starting ages and intervals, DBT averted 7.4 to 10.5 breast cancer deaths per 1000 average-risk women screened and 23.2 to 33.6 per 1000 women with 4 times higher-than-average risk. Across all RR levels, DBT with supplemental MRI for women with extremely dense breasts (DBT+MRId) averted 0.1 to 0.8 additional breast cancer deaths and resulted in 22 to 186 additional false-positive biopsy recommendations. False-positive biopsies per breast cancer death averted for biennial DBT+MRId for women with 2 times higher-than-average risk were similar to those associated with DBT in average-risk women. For all risk groups, biennial DBT+MRId starting at age 50 years was more effective but less cost-effective than DBT starting at age 45 years. The ICERs were sensitive to cancer risk, MRI costs, and false-positive biopsy rates. Subgroups considered risk and breast density only. Supplemental MRI for women aged 40 years or older with extremely dense breasts and higher-than-average risk (RR ≥2.0) had harm-benefit ratios similar to biennial DBT alone and could be cost-effective if MRI costs and false-positive biopsy rates are reduced. National Cancer Institute.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 5: Objective function inputs.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 5: Objective function inputs.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 8: Observed and predicted uterine cancer incidence-based mortality.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 8 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 8: Observed and predicted uterine cancer incidence-based mortality.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 2: Histologic groupings from SEER 18.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 2: Histologic groupings from SEER 18.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 3: Variables available to define extent of disease and AJCC stage.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 3: Variables available to define extent of disease and AJCC stage.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 1: Model characteristics.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 1: Model characteristics.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 9 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 9: Observed and projected incidence and 5-year survival of uterine cancer overall and stratified by histology with projected trends in obesity and hysterectomy rates.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 9 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 9: Observed and projected incidence and 5-year survival of uterine cancer overall and stratified by histology with projected trends in obesity and hysterectomy rates.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Figure 1: Projected age adjusted uterine cancer incidence and incidence-based mortality among women aged 40+ stratified by race and ethnicity to 2050.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Figure 1: Projected age adjusted uterine cancer incidence and incidence-based mortality among women aged 40+ stratified by race and ethnicity to 2050.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (7) , 1156-1166
Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Background: To develop a natural history model for uterine cancer calibrated to population-based incidence and mortality data to project future trends in the disease through 2050. Methods: We developed a state-transition microsimulation model of uterine cancer. The model begins at 18 years of age and simulates Black and White patients, includes transition states for precursor lesions, and separately models endometrioid and nonendometrioid tumors. The model was calibrated to population-based incidence and mortality data using parameter extrapolation. Results: The model closely fit population-based incidence and mortality data of uterine cancer. From 2020 to 2050, the incidence of uterine cancer is projected to increase in White women to 74.2 cases per 100,000 (compared with 57.7 cases per 100,000 in 2018) and increase to 86.9 per 100,000 (compared with 56.8 cases per 100,000 in 2018) in Black women. Among White women, incidence-based mortality will increase from 6.1 per 100,000 in 2018 to 11.2 per 100,000 in 2050, whereas incidence-based mortality in Black women will increase from 14.1 per 100,000 to 27.9 per 100,000. Endometrioid tumors are expected to increase considerably in both White and Black women; White women will experience only a slight increase in nonendometrioid tumors, whereas the incidence of these tumors will increase substantially in Black women. Conclusions: The incidence and mortality of uterine cancer are projected to increase substantially over the next three decades. Black women will experience a disproportionate increase in the disease. Impact: Projecting the incidence and mortality of uterine cancer can facilitate future cancer control efforts.
- 1 July 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (7) , 1156-1166
Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Background: To develop a natural history model for uterine cancer calibrated to population-based incidence and mortality data to project future trends in the disease through 2050. Methods: We developed a state-transition microsimulation model of uterine cancer. The model begins at 18 years of age and simulates Black and White patients, includes transition states for precursor lesions, and separately models endometrioid and nonendometrioid tumors. The model was calibrated to population-based incidence and mortality data using parameter extrapolation. Results: The model closely fit population-based incidence and mortality data of uterine cancer. From 2020 to 2050, the incidence of uterine cancer is projected to increase in White women to 74.2 cases per 100,000 (compared with 57.7 cases per 100,000 in 2018) and increase to 86.9 per 100,000 (compared with 56.8 cases per 100,000 in 2018) in Black women. Among White women, incidence-based mortality will increase from 6.1 per 100,000 in 2018 to 11.2 per 100,000 in 2050, whereas incidence-based mortality in Black women will increase from 14.1 per 100,000 to 27.9 per 100,000. Endometrioid tumors are expected to increase considerably in both White and Black women; White women will experience only a slight increase in nonendometrioid tumors, whereas the incidence of these tumors will increase substantially in Black women. Conclusions: The incidence and mortality of uterine cancer are projected to increase substantially over the next three decades. Black women will experience a disproportionate increase in the disease. Impact: Projecting the incidence and mortality of uterine cancer can facilitate future cancer control efforts.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 4: Transition bounds within the model.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States
Supplemental Table 4: Transition bounds within the model.